Positron subsidiary Manhattan Isotope Technology (MIT) has received approval of its radioactive materials license amendment from the radiation control program at the Texas Department of State Health Services.
The amendment will allow for the receipt and processing of solutions that contain strontium-82 (Sr-82) and multiple other radioisotopes, according to Positron. Over the next six months, MIT will obtain Sr-82 target solutions from providers outside the U.S. for final purification into pharmaceutical-grade Sr-82 at its facility in Lubbock, TX.
Strontium-82 is used to produce generators for rubidium-82, a radioisotope used in cardiac PET studies. MIT will begin supporting Sr-82 supply in 2012, Positron said.
